Russia invaded Ukraine on 24 of February 2022. Stand with Ukraine and support us in a fight for freedom and democracy in Europe.  Stand with Ukraine!  Join us
search
The #1 Medical Tourism Platform since 2014

Best Chemotherapy for breast cancer doctors: TOP 94 doctors

author
Content meets the Bookimed Editorial Policy and is medically reviewed by
Fahad Mawlood - General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
Fredi Aviv
Hematologist
32 years of experience
4.4
135 reviews
Israel, Tel Aviv
Sourasky Medical Center (Ichilov)

Fredi Aviv

Hematologist
32 years of experience
Dr. Fredi Aviv is an Oncohematologist with 31 years of experience at the Sourasky Medical Center (Ichilov Clinic).Read more
Sezer Saglam
Clinical oncologist
27 years of experience
5.0
13 reviews
Turkey, Istanbul
Group Florence Nightingale Hospitals

Sezer Saglam

Clinical oncologist
27 years of experience
Professional ExperienceGayrettepe Florence Nigthingale HospitalMedical Oncology DepartmentBesiktas/Istanbul/Turkey (ongoing) Education:He became Professor (22/April /2016)Medical Oncology Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)Istanbul University Oncology Institue,Department of Medical Oncology Medical Oncology Fellowship (December 2001-December2004)Istanbul University, Istanbul Medical Faculty Hemodialysis Traning (May1996-January1997)Istanbul University ,bCerrahpasa Medical Faculty Internal Medicine Residency (November 1991-November 1996)Istanbul University ,bCerrahpasa Medical Faculty Ege University Medical Faculty (1985-1991) Professional Experience February 1999-November 2001Metropolitan Florence Nigthingale HospitalAmerican Cancer Center, Gayrettepe/İstanbul April1997- October 1998Bayraktar Dialysis CenterGüngören/ Istanbul Membership Turkish Medical Oncology AssociationENET(European Neuroendocrine Tumour Society)ESMOASCORead more
Cho Jae-Yong
4.5
42 reviews
Republic of Korea, Seoul
Severance Hospital

Oncologist

Read more
Armando Santoro
Clinical oncologist
44 years of experience
Italy, Milan
HUMANITAS RESEARCH HOSPITAL

Armando Santoro

Clinical oncologist
44 years of experience
Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities. He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.  In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.  Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.  Current Positions:  .Since 1997, he is the Director of the Department of Medical Oncology and Haematology, at Istituto Clinico Humanitas, Milan. Also, he is Member of the Ethics Committee of Istituto Clinico Humanitas and Director of Clinical Research in the same Institute since 2007. - Since 2008, he is Member of the Planning Committee, Ministry of Work and of Health and Social Politics, Rome, Italy. - Since October 2008, Professor Santoro is Counsellor of the Board of Directors of the Fondazione Humanitas for Research of Rozzano, Italy. - Since November 2008, he is Expert Member of the National Centre for the Prevention and Control of Disease, Ministry of Work and of Health and Social Politics (Rome, Italy). - Since February 2009, he is National Representative preparatory actions for the "European Partnership for Action against Cancer" Ministry of Work and of Health and Social Politics (Rome, Italy). - Since February 2009, Professor Santoro is member of National Italian Committee on the Research Network in Oncology, Ministry of Work and of Health and Social Politics (Rome, Italy). - Since May 2009, he is Coordinator of the Oesophageal-Stomach Cancer Group Coordinator of the Liver and Biliary Tree Cancer Group, Regional Oncology Commission – Lombardy Oncology Network.   In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).      Publications: santoro%a - Search Results - PubMed (nih.gov)  Read more
Muhammed Gomec
Colorectal surgeon
15 years of experience
5.0
1 review

Muhammed Gomec

Colorectal surgeon
15 years of experience
Turkey, Sivas
Medicana Sivas Hospital
Alandag Celal
Clinical oncologist
15 years of experience
5.0
1 review

Alandag Celal

Clinical oncologist
15 years of experience
Turkey, Sivas
Medicana Sivas Hospital
Phd Viola Fox
Hematologist
12 years of experience
4.6
52 reviews

Phd Viola Fox

Hematologist
12 years of experience
Germany, Solingen
Medical Center in Solingen
Nail Paksoy
Oncologist/mammologist
13 years of experience
4.0
1 review
Turkey, Istanbul
Medipol Bahçelievler Hospital

Nail Paksoy

Oncologist/mammologist
13 years of experience

accreditations:

ESMO Board Certification in Medical Oncology
PROFESSIONAL EXPERIENCE2011-2012Erzurum Koprukoyu State HospitalDepartment: General Medicine2012-2017Istanbul University Cerrahpaşa Medical FacultyDepartment: Internal Medicine06/2017-10/2017Istanbul Gaziosmanpasa Taksim Training and Research HospitalDepartment: Internal Medicine10/2017-11/2018Istanbul University Istanbul Medical FacultyDepartment: Allergy and Immunology Fellowship2018/2022Istanbul University Oncology InstituteDepartment: Medical Oncology Fellowship2022-2023Tekirdag City HospitalDepartment: Medical Oncology Specialist2023-presentIstanbul Medipol University Medipol Bahcelievler Private HospitalDepartment: Medical Oncology Assoc. Prof. EDUCATION2005-2011Medical EducationSivas Cumhuriyet University Medical Faculty, Sivas, Turkey2012-2017Internal MedicineIstanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey2017-2018Allergy-Immunology FellowshipIstanbul University Istanbul Medical FacultyDepartment of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey2018-2022Medical Oncology FellowshipIstanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey2022ESMO Board Certification in Medical Oncology10th September 2022 in Paris, France.2023Medical Oncology Assoc. Prof.Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey INTERNATIONAL CLINICAL TRIALS:1. Astefania - ROCHETitle: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyRole: Subinvestigator2. PFİZERTitle: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLCRole: Subinvestigator3. RECITE - AMGENTitle: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerRole: Subinvestigator4. NAVIGATE - BAYERTitle: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsRole: Subinvestigator5. RUBY - Tesaro (PRA)Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial CancerRole: Subinvestigator6. ENGOT-ov43/GOG-3036 - MSDTitle: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)Role: Subinvestigator7. ASTRA ZENECATitle: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.Role: Subinvestigator8. ROSY-O - ASTRA ZENECATitle: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibRole: Subinvestigator INTERNATIONAL PUBLICATIONSI. Published journal articles indexed by SCI, SSCI, and AHCIWeekly Paclitaxel in Classic Kaposi SarcomaAuthors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.Journal: Medicine, 102(5)Carboplatin Desensitization in Ovarian CarcinomaAuthors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.Journal: Medicine, 101(45), e31726High-Dose Chemotherapy for Ewing’s SarcomaAuthors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.Journal: Medicine, 101(49), e32213Multidrug Refractory TFE3(+) Renal Cell CarcinomaAuthors: Paksoy, Nail, et al.Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221Crizotinib Efficacy in NSCLC with MET AlterationsAuthors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.Journal: Medicine, 101(50), e32368Clinicopathological Features in ALK Mutant NSCLCAuthors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.Journal: Medicine, 101(34)PSMA-Based Tumor Burden in Prostate CancerAuthors: HAS SIMSEK, Duygu, et al.Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690Atezolizumab in Metastatic Urothelial CarcinomaAuthors: TURAL, Deniz, et al.Journal: European Urology Focus, 2021, 7.5: 1061-1066Pulmonary Sarcomatoid CarcinomaAuthors: FERHATOGLU, Ferhat, et al.Journal: Oncology Research and Treatment, 2021, 44.11: 590-601Prognostic Factors in Atezolizumab-Treated Urothelial CarcinomaAuthors: TURAL, Deniz, et al.Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513Atezolizumab with Chemotherapy in Small Cell Lung CancerAuthors: GÜRBÜZ, Mustafa, et al.Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic CancerAuthors: AY, Seval, et al.Journal: Journal of Chemotherapy, 2022, 1-7Trastuzumab Emtansine in Older HER2-Positive Breast Cancer PatientsAuthors: CIL, Ibrahim, et al.Journal: Tumori Journal, 2022, 108.1: 19-25Real-Life Efficacy of Osimertinib in Advanced NSCLCAuthors: HIZAL, Mutlu, et al.Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508ALK-Positive Cells Percentage and Alectinib EfficacyAuthors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148Real-World Data on Alectinib in ALK-Positive NSCLCAuthors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.Journal: Future Oncology, 18(23), 2573-2582Prognostic Factors in Metastatic RCC with T790M MutationAuthors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsFLOT Regimen in Metastatic Gastric CancerAuthors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.Journal: Journal of Cancer Research and TherapeuticsDesensitization Protocol in Lenalidomide Hypersensitivity ReactionsAuthors: DEMIR, Semra, et al.Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397Factors Associated with Diagnostic Skin Test Positivity in PPI HypersensitivityAuthors: ÖZDEMIR, Seçil Kepil, et al.Journal: Allergy, 2019, 74.6: 1187-1190Efficacy of Capecitabine and Temozolomide in Neuroendocrine TumorsAuthors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.Journal: The Oncologist, oyad257Subsequent Treatments in Hormone-Positive Breast Cancer ProgressionAuthors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.Journal: BMC cancer, 23(1), 192Termination of Trastuzumab in HER2-Positive Metastatic Breast CancerAuthors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.Journal: Scientific Reports, 13(1), 8779Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast CancerAuthors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.Journal: Journal of Cancer Research and Clinical Oncology, 1-9Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast CancerAuthors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.Journal: European Journal of Breast Health, 19(2), 128Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast CancerAuthors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.Journal: Future Oncology, 19(10), 727-736Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma PatientsAuthors: Dogan, I., Paksoy, N., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsSingle-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma PatientsAuthors: Dogan, I., Paksoy, N., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsOutcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain MetastasesAuthors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.Journal: Journal of Cancer Research and TherapeuticsFLOT Regimen in First-Line Treatment of Metastatic Gastric CancerAuthors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.Journal: Journal of Cancer Research and TherapeuticsPrognostic Factors of Perioperative FLOT Regimen in Operable Gastric CancerAuthors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.Journal: [Not specified]Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi SarcomaAuthors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.Journal: Medicine, 102(39), e35383Comparison of Second-Line Treatments in Metastatic Renal Cell CarcinomaAuthors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.Journal: Medicine, 102(41), e35245Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGYPredictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of PulmonologyLaterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye Thesis:Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combinationAuthors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group studyAuthors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancerAuthors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)Efficacy of temozolomide in pretreated patients with metastatic sarcomaAuthors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumorsAuthors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcomaAuthors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastasesAuthors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinomaAuthors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk studyAuthors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiencesAuthors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)  Read more
Luca Gianni
4.5
55 reviews
Italy, Milan
San Raffaele

Medical Oncologist

Read more
Andrzej Wronski
4.3
3 reviews
Poland, Otwock
European Health Center Otwock

Oncologist

Read more
Kim Tae Joong
4.5
22 reviews
Republic of Korea, Seoul
Samsung Medical Center

Gynecologist. Oncogynecologist

Read more
Aleix Prat
Clinical oncologist
21 years of experience
4.3
6 reviews
Spain, Barcelona
Hospital Quiron Barcelona

Aleix Prat

Clinical oncologist
21 years of experience

accreditations:

SOLTI
The Breast International Group
Dr. Prat is a clinical scientist with expertise in breast cancer research, clinical trials, and gene expression. He has a MD degree from the University of Barcelona and completed a medical oncology fellowship at the Vall d'Hebron Institute of Oncology. He is Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute, President of the Board of Directors of SOLTI, and member of the Executive Committee of The Breast International Group. He has published 160 publications with 13.479 citations and is a Tenure-Track Professor of Barcelona University and Director of the Breast Pathology – Senology Master´s degree.Read more
Severine Iborra
Obstetrician-gynecologist
16 years of experience
4.6
52 reviews
Germany, Solingen
Medical Center in Solingen

Severine Iborra

Obstetrician-gynecologist
16 years of experience

accreditations:

Deutsche Krebsgesellschaft
European Society of Gynecological Oncology
Dr. Sebastian Hentsch is a Head of Gynecology and Obstetrics Department in Solingen Klinikum. He specializes in gynecology, minimally invasive gynecological surgeries, and deliveries. He is a member of leading medical associations concerning Gynecology and Gynecological Oncology, and speaks German, English, French, and Russian.Read more
Elena Zorina
4.5
13 reviews
Russian Federation, Moscow
Yauza Medical Center

Chief Oncologist, Specialist in the treatment of tumors of the different localizations

Read more
Justus Duyster
5.0
2 reviews
Germany, Freiburg
Medical Center - University of Freiburg (Uniklinik Freiburg)

Doctor, Oncologist

Read more
Germany, Dusseldorf
The University Hospital in Dusseldorf

Head of Cancer Center

Read more
Germany, Dusseldorf
The University Hospital in Dusseldorf